New Results
Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains
Nikhil Faulkner, Kevin W. Ng, Mary Wu, Ruth Harvey, Marios Margaritis, Stavroula Paraskevopoulou, Catherine F. Houlihan, Saira Hussain, Maria Greco, William Bolland, Scott Warchal, Judith Heaney, Hannah Rickman, Moira J. Spyer, Daniel Frampton, Matthew Byott, Tulio de Oliveira, Alex Sigal, Svend Kjaer, Charles Swanton, Sonia Gandhi, Rupert Beale, Steve J. Gamblin, Crick COVID-19 Consortium, John McCauley, Rodney Daniels, Michael Howell, David L.V. Bauer, Eleni Nastouli, SAFER Investigators, View ORCID ProfileGeorge Kassiotis
doi: https://doi.org/10.1101/2021.03.01.433314
Nikhil Faulkner
1Retroviral Immunology, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
20Gene Therapy Group, National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK
Kevin W. Ng
1Retroviral Immunology, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
Mary Wu
2High Throughput Screening STP, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
Ruth Harvey
3Worldwide Influenza Centre, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
Marios Margaritis
10Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London NW1 2BU, UK
Stavroula Paraskevopoulou
10Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London NW1 2BU, UK
Catherine F. Houlihan
10Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London NW1 2BU, UK
11Division of Infection and Immunity, UCL, London WC1E 6BT, UK
Saira Hussain
3Worldwide Influenza Centre, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
4RNA Virus Replication Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
Maria Greco
4RNA Virus Replication Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
William Bolland
1Retroviral Immunology, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
Scott Warchal
2High Throughput Screening STP, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
Judith Heaney
10Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London NW1 2BU, UK
Hannah Rickman
10Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London NW1 2BU, UK
Moira J. Spyer
10Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London NW1 2BU, UK
12Department of Population, Policy and Practice, Great Ormond Street ICH, UCL, London WC1N 1EH, UK
Daniel Frampton
11Division of Infection and Immunity, UCL, London WC1E 6BT, UK
Matthew Byott
10Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London NW1 2BU, UK
Tulio de Oliveira
13School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban 4001, South Africa
14KwaZulu-Natal Research Innovation and Sequencing Platform, Durban 4001, South Africa
15Centre for the AIDS Programme of Research in South Africa, Durban 4001, South Africa
17Department of Global Health, University of Washington, Seattle, USA
Alex Sigal
13School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban 4001, South Africa
16Africa Health Research Institute, Durban 4001, South Africa
18Max Planck Institute for Infection Biology, Berlin 10117, Germany
Svend Kjaer
5Structural Biology STP, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
Charles Swanton
6Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
Sonia Gandhi
7Neurodegradation Biology Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
Rupert Beale
8Cell Biology of Infection Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
Steve J. Gamblin
9Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
John McCauley
3Worldwide Influenza Centre, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
Rodney Daniels
3Worldwide Influenza Centre, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
Michael Howell
2High Throughput Screening STP, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
David L.V. Bauer
4RNA Virus Replication Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
Eleni Nastouli
10Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London NW1 2BU, UK
12Department of Population, Policy and Practice, Great Ormond Street ICH, UCL, London WC1N 1EH, UK
George Kassiotis
1Retroviral Immunology, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
19Department of Infectious Disease, St Mary’s Hospital, Imperial College London, London W2 1PG, UK

Abstract
We examined the immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant B.1.1.7 that arose in the United Kingdom and spread globally. Antibodies elicited by B.1.1.7 infection exhibited significantly reduced recognition and neutralisation of parental strains or of the South Africa B.1.351 variant, than of the infecting variant. The drop in cross-reactivity was more pronounced following B.1.1.7 than parental strain infection, indicating asymmetric heterotypic immunity induced by SARS-CoV-2 variants.
Competing Interest Statement
The authors have declared no competing interest.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Posted March 01, 2021.
Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains
Nikhil Faulkner, Kevin W. Ng, Mary Wu, Ruth Harvey, Marios Margaritis, Stavroula Paraskevopoulou, Catherine F. Houlihan, Saira Hussain, Maria Greco, William Bolland, Scott Warchal, Judith Heaney, Hannah Rickman, Moira J. Spyer, Daniel Frampton, Matthew Byott, Tulio de Oliveira, Alex Sigal, Svend Kjaer, Charles Swanton, Sonia Gandhi, Rupert Beale, Steve J. Gamblin, Crick COVID-19 Consortium, John McCauley, Rodney Daniels, Michael Howell, David L.V. Bauer, Eleni Nastouli, SAFER Investigators, George Kassiotis
bioRxiv 2021.03.01.433314; doi: https://doi.org/10.1101/2021.03.01.433314
Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains
Nikhil Faulkner, Kevin W. Ng, Mary Wu, Ruth Harvey, Marios Margaritis, Stavroula Paraskevopoulou, Catherine F. Houlihan, Saira Hussain, Maria Greco, William Bolland, Scott Warchal, Judith Heaney, Hannah Rickman, Moira J. Spyer, Daniel Frampton, Matthew Byott, Tulio de Oliveira, Alex Sigal, Svend Kjaer, Charles Swanton, Sonia Gandhi, Rupert Beale, Steve J. Gamblin, Crick COVID-19 Consortium, John McCauley, Rodney Daniels, Michael Howell, David L.V. Bauer, Eleni Nastouli, SAFER Investigators, George Kassiotis
bioRxiv 2021.03.01.433314; doi: https://doi.org/10.1101/2021.03.01.433314
Subject Area
Subject Areas
- Biochemistry (9619)
- Bioengineering (7110)
- Bioinformatics (24915)
- Biophysics (12642)
- Cancer Biology (9979)
- Cell Biology (14386)
- Clinical Trials (138)
- Developmental Biology (7968)
- Ecology (12133)
- Epidemiology (2067)
- Evolutionary Biology (16008)
- Genetics (10937)
- Genomics (14764)
- Immunology (9889)
- Microbiology (23718)
- Molecular Biology (9493)
- Neuroscience (50964)
- Paleontology (370)
- Pathology (1544)
- Pharmacology and Toxicology (2688)
- Physiology (4031)
- Plant Biology (8677)
- Synthetic Biology (2403)
- Systems Biology (6446)
- Zoology (1346)